The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M.
Vitale G, et al.
Biotechnol Adv. 2012 Jan-Feb;30(1):169-84. doi: 10.1016/j.biotechadv.2011.08.001. Epub 2011 Aug 17.
Biotechnol Adv. 2012.
PMID: 21871555